ABL1 and acute lymphoblastic leukemia: This demonstrates a B lineage specific requirement of Src kinases for BRC/ABL1 driven malignancies, and is consistent with synergy of pan Src kinase inhibitor CGP76030 with imatinib mesylate in treating BCR/ABL1-induced B ALL but not CML.